skip to main content

Doxazosin-associated orthostatic hypotension in an older man with hypertension and benign prostatic enlargemen

Instant feedback + full explanation. One question, done properly.

HardBeers CriteriaDoxazosin-associated orthostatic hypotension in an older man with hypertension and benign prostatic enlargementSCE Geriatric Medicine

An 84-year-old man is reviewed after three falls preceded by light-headedness on standing. He takes ramipril 10 mg once daily, amlodipine 5 mg once daily, indapamide modified-release 1.5 mg once daily and doxazosin 8 mg at night. Doxazosin was introduced as fourth-line treatment for hypertension and also improved his lower urinary tract symptoms. His seated blood pressure is 134/70 mmHg. After standing for 3 minutes it is 102/58 mmHg and reproduces his symptoms. He is euvolaemic, and examination, ECG, haemoglobin and glucose provide no alternative explanation. Potassium is 4.8 mmol/L and eGFR 52 mL/min/1.73 m². He remains bothered by urinary frequency, poor stream and nocturia, with an International Prostate Symptom Score of 19. Digital rectal examination suggests a benign 55 g prostate; PSA is 2.3 micrograms/L and post-void residual volume is 80 mL. There is no urinary retention, infection or suspicion of prostate cancer. Which is the most appropriate medication strategy?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Withdraw doxazosin and start finasteride, with review of standing blood pressure and urinary symptoms

Explanation lettering: E = shown as A · D = shown as B · B = shown as D · A = shown as E

Doxazosin is a non-selective peripheral alpha-1 blocker. The Beers Criteria identify this class as inappropriate for hypertension in older adults because of its high risk of orthostatic hypotension and recommend avoiding it in patients with syncope attributable to orthostatic blood-pressure changes. Here, the large symptomatic postural fall, recurrent falls and absence of an alternative cause make withdrawal the priority, despite its dual indication. His bothersome LUTS should not simply be ignored: a 55 g prostate and PSA above 1.4 micrograms/L indicate increased progression risk, for which NICE supports a 5-alpha-reductase inhibitor such as finasteride. Its delayed onset should be discussed and symptoms reviewed. Standing, rather than solely seated, blood pressure should guide subsequent antihypertensive decisions. A retains the drug causing clinically important hypotension; adding finasteride does not mitigate that immediate harm. C appears attractive because tamsulosin is relatively uroselective, but its UK SmPC contraindicates initiation in someone with a history of orthostatic hypotension. D uses a possible fourth-line antihypertensive without first establishing that replacement is required and undertreats bothersome, progression-prone LUTS. E may reduce diuretic-related hypotension, but the euvolaemic patient has a classic alpha-blocker adverse effect; retaining doxazosin and monitoring only seated pressure fails to address the discriminator.

Reference: American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults (2023) — https://pubmed.ncbi.nlm.nih.gov/37139824/ NICE CG97: Lower urinary tract symptoms in men — Recommendations (Current guidance checked 26 August 2026) — https://www.nice.org.uk/guidance/cg97/chapter/recommendations Tamsulosin hydrochloride SUN Pharma 400 micrograms prolonged-release hard capsules — SmPC (23 April 2025) — https://www.medicines.org.uk/emc/product/2508/smpc